Histamine and H1-antihistamines: Celebrating a century of progress

Seizures Induced by Desloratadine, A Second-Generation Antihistamine: Clinical Observations

“…In contrast to previous findings, 6 we found a proconvulsive effect of desloratadine. In our patients, the increased susceptibility to seizures during desloratadine treatment let us to speculate that a mutation of the multidrug-resistance gene 1 produces an "abnormal P-gp".…”

Seizures Induced by Desloratadine, A Second-Generation Antihistamine: Clinical Observations

“…In contrast to previous findings, 6 we found a proconvulsive effect of desloratadine. In our patients, the increased susceptibility to seizures during desloratadine treatment let us to speculate that a mutation of the multidrug-resistance gene 1 produces an "abnormal P-gp".…”

Effect of Aromatherapy on Uremic Pruritus among Patients Undergoing Hemodialysis

“…As regards antihistaminic drugs intake the current study reported that more than half received intravenous medication. The current study coincides with [35] who reported that more than half take anti histaminic drugs intravenous. Another study done by [36] reported that majority of study participants take antihistaminic drugs intravenously.…”

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

“…In this pharmacokinetics study the median T max of bilastine after single dose administration was 2.13 h, which is comparable to that found for ophthalmic formulations of olopatadine (0.5-2 h), epinastine (2 h), ketotifen (2-4 h) or azelastine (5.3 h) [38]. Ophthalmic bilastine presented a considerably longer halflife, 7.88 h, than ophthalmic olapatadine 0.77%, which had a half-life of 3.40 h [39].…”

Seizures Induced by Desloratadine, A Second-Generation Antihistamine: Clinical Observations

“…In contrast to previous findings, 6 we found a proconvulsive effect of desloratadine. In our patients, the increased susceptibility to seizures during desloratadine treatment let us to speculate that a mutation of the multidrug-resistance gene 1 produces an "abnormal P-gp".…”

Effect of Aromatherapy on Uremic Pruritus among Patients Undergoing Hemodialysis

“…As regards antihistaminic drugs intake the current study reported that more than half received intravenous medication. The current study coincides with [35] who reported that more than half take anti histaminic drugs intravenous. Another study done by [36] reported that majority of study participants take antihistaminic drugs intravenously.…”

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

“…In this pharmacokinetics study the median T max of bilastine after single dose administration was 2.13 h, which is comparable to that found for ophthalmic formulations of olopatadine (0.5-2 h), epinastine (2 h), ketotifen (2-4 h) or azelastine (5.3 h) [38]. Ophthalmic bilastine presented a considerably longer halflife, 7.88 h, than ophthalmic olapatadine 0.77%, which had a half-life of 3.40 h [39].…”

Seizures Induced by Desloratadine, A Second-Generation Antihistamine: Clinical Observations

“…In contrast to previous findings, 6 we found a proconvulsive effect of desloratadine. In our patients, the increased susceptibility to seizures during desloratadine treatment let us to speculate that a mutation of the multidrug-resistance gene 1 produces an "abnormal P-gp".…”

Effect of Aromatherapy on Uremic Pruritus among Patients Undergoing Hemodialysis

“…As regards antihistaminic drugs intake the current study reported that more than half received intravenous medication. The current study coincides with [35] who reported that more than half take anti histaminic drugs intravenous. Another study done by [36] reported that majority of study participants take antihistaminic drugs intravenously.…”

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation

“…In this pharmacokinetics study the median T max of bilastine after single dose administration was 2.13 h, which is comparable to that found for ophthalmic formulations of olopatadine (0.5-2 h), epinastine (2 h), ketotifen (2-4 h) or azelastine (5.3 h) [38]. Ophthalmic bilastine presented a considerably longer halflife, 7.88 h, than ophthalmic olapatadine 0.77%, which had a half-life of 3.40 h [39].…”